{"id":"W2955574442","doi":"10.1093/annonc/mdz155.186","title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Bevacizumab; Adjuvant therapy; Hepatocellular carcinoma; Oncology; Internal medicine; Adjuvant; Placebo; Clinical endpoint; Surgery; Cancer; Randomized controlled trial; Immunotherapy; Nivolumab; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192152,0.0009535417,0.002234043,0.0003368807,0.0003830012,0.0009662653,0.0006265515,0.0009580034,0.00286509],"category_scores_gemma":[0.0008913378,0.0005208607,0.001601645,0.000399031,0.0008491352,0.001012478,0.0003077381,0.003370325,0.0005890342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009648923,"about_ca_system_score_gemma":0.001495942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001812586,"about_ca_topic_score_gemma":0.005454456,"domain_scores_codex":[0.9996578,0.0001492825,0.00001433284,0.00006307311,0.00002563404,0.0000900129],"domain_scores_gemma":[0.9994325,0.0001229752,0.0000798917,0.00004806083,0.00003261319,0.0002838031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8776977,0.0393099,0.004958471,0.0004568266,0.001541664,0.0001286041,0.0002122626,0.001271311,0.01284705,0.0002253027,0.002038962,0.05931202],"study_design_scores_gemma":[0.7302978,0.2549642,0.009078696,0.00002761128,0.0008698397,0.0001324462,0.00008062547,0.0009678818,0.001529573,0.0002228556,0.001796583,0.00003187891],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994616,0.001913102,0.0003268378,0.0004860955,0.0002019967,0.0008948994,0.0004752444,0.0000503141,0.00103546],"genre_scores_gemma":[0.9916909,0.001805533,0.00134448,0.0008565103,0.0001626516,0.001316954,0.001072715,0.00003079239,0.001719452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00286509,"threshold_uncertainty_score":0.009584606,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06692529537401778,"score_gpt":0.3296907541364201,"score_spread":0.2627654587624023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}